Product deep-dives, clinical perspectives, and behind-the-scenes notes from the team building Rucja Health.
Plasma EBV DNA is detectable in approximately 90% of NPC patients at diagnosis, making it a reliable quantitative surveillance biomarker. The clinical value lies not in individual readings but in tracking the velocity of change between successive draws - a step most clinic platforms still leave to manual calculation.
Post-HIPEC surveillance for peritoneal mesothelioma demands precise timing across five or more years. This article explains why follow-up schedules slip and what clinic operators can do about it.
Adrenocortical carcinoma recurs in more than 64% of patients after surgery, and cortisol hypersecretion is a consistent predictor of that recurrence. This article examines where ACC hormone surveillance protocols break down in clinic operations and how structured lab tracking closes the gap.
Anaplastic thyroid carcinoma treatment produces grade 3 or 4 toxicity in over 40 percent of patients on BRAF-targeted regimens. Most oncology clinic workflows are not structured to detect, grade, and act on that burden before it drives avoidable dose interruptions.
Appendiceal adenocarcinoma surveillance requires more than a generic GI follow-up template. This guide covers the three-marker lab panel, post-CRS/HIPEC imaging intervals, and the coordination failures that let surveillance drift.
Muscle-invasive bladder cancer teams generate TP53 and FGFR3 mutation records that carry elevated re-identification risk and trigger layered federal and state privacy obligations. This article outlines the specific encryption, access control, and audit trail requirements that protect them inside a HIPAA-ready oncology platform.
Follicular lymphoma transforms to aggressive disease at an annual rate of approximately 2-3%, but standard follow-up schedules impose fixed rhythms on a variable-risk disease. The result is a measurable detection gap, concentrated in the POD24 window, that structured lab monitoring and scheduling logic can help close.
PD-L1 expression varies significantly across squamous cell lung cancer tumors, creating real uncertainty in immunotherapy response prediction. Here is what the research shows and what it means for clinic data workflows.
KIT mutation subtype drives significantly different outcomes in GIST, but most clinics store that data in unstructured PDFs rather than queryable fields. Rucja's Lab Intelligence module extracts exon-level mutation data from NGS reports and surfaces it alongside NIH risk stratification inputs at every follow-up visit.
Primary CNS lymphoma carries one of the highest relapse rates in hematology, with most relapses concentrated in the first two years after treatment. Coordination gaps across neuro-oncology, radiology, and ophthalmology allow surveillance intervals to drift before any clinician notices.
Most asymptomatic Waldenström macroglobulinemia patients spend years before reaching a treatment threshold. Clinics that apply uniform monitoring intervals and review IgM in isolation routinely over-escalate indolent disease and consume capacity that higher-acuity patients need.
Pheochromocytoma has one of the highest hereditary rates in oncology, with 30 to 40 percent of cases linked to a germline mutation. Securing that genetic data across multi-provider care teams requires more than HIPAA awareness - it requires the right platform architecture.
Calcitonin doubling time predicts survival in medullary thyroid cancer more reliably than static values alone, yet most clinics track it without automated velocity computation. Here is where that process breaks down.
Locoregional recurrence affects nearly half of sinonasal squamous cell carcinoma patients, with a mean onset at 12.1 months post-treatment. Most clinics have no structured mechanism to track whether each imaging event in the post-resection schedule has been completed on time.
Chromogranin A is the most widely used serum marker in GEP-NET surveillance, but guideline disagreement, assay variability, and common medication confounders mean its clinical value depends almost entirely on how consistently it is tracked. Here is where clinic infrastructure typically falls short.
MCPyV antibody titers and ctDNA results arrive as unstructured PDF lab reports, often from different vendors on a three-month cadence. Rucja Lab Intelligence extracts, normalizes, and trends those values automatically so Merkel cell carcinoma surveillance teams work from a sequential signal rather than isolated data points.
Soft tissue sarcoma clinics routinely complete neoadjuvant chemotherapy and book the operating room, but the pre-surgical MRI that should connect those two milestones often falls through the cracks. This article examines why the imaging gap exists and what structured workflow tools can do to close it.
Cholangiocarcinoma clinics running FGFR2 and IDH1 profiling accumulate a dense set of actionable genetic records. Here is what it takes to protect them.
Cervical cancer HPV clearance surveillance spans at least five years and crosses multiple care settings. Fragmented data systems let patients slip through monitoring gaps before clearance is confirmed.
HPV ctDNA testing can resolve up to 92 percent of clinically indeterminate findings in anal cancer surveillance, yet most clinics lack the workflow infrastructure to order, receive, and trend these results reliably.
Serial SMRP monitoring can detect mesothelioma progression before imaging confirms it. Here is where clinic workflows lose that signal, and what structured velocity tracking looks like in practice.
Concurrent chemoradiation for esophageal cancer creates compounding toxicity risks across a tight five-to-six-week treatment window. This piece identifies where monitoring gaps form and how structured clinic workflows address them.
BCL2 and MYC translocation results are among the most sensitive genomic records a DLBCL clinic handles. This article examines how oncology teams can secure FISH reports, enforce role-based access, and meet HIPAA-ready standards across multi-disciplinary workflows.
Imaging surveillance gaps in metastatic urothelial cancer let disease progression go undetected between treatment cycles. This article examines where those gaps form and how Rucja's scheduling and protocol-tracking tools keep CT intervals on time.
When head and neck cancer patients move from surgery to adjuvant chemotherapy, structured toxicity data routinely fails to follow. This article examines the three failure points that create the gap and what clinic operators should demand from platform software.
Serial LDH monitoring in small cell lung cancer provides an early signal of treatment response or progression. Most clinic platforms do not surface the velocity trend, leaving oncologists to detect a critical shift only after it has already widened.
Post-chemotherapy surveillance for testicular cancer spans years of AFP, beta-HCG, and imaging follow-up. Clinic operations teams need structured scheduling and trend-level lab data to keep that protocol on track.
Glioblastoma recurs in 6 to 9 months on average, yet fewer than half of patients receive MRI on the schedule their guidelines recommend. This article examines where the surveillance workflow breaks down and how protocol-driven scheduling prevents gaps from forming.
EBV-positive Hodgkin lymphoma programs generate serial viral biomarker data across multiple providers over months of treatment. This article covers the data security architecture and governance controls that protect that data at every handoff point.
A single AFP reading tells you where a patient stands today. AFP velocity tells you where they are heading, and Rucja's Lab Intelligence tracks that trajectory automatically so HCC risk surfaces before a conventional threshold is crossed.
MRD testing in ALL is only clinically meaningful when bone marrow assessments land at the right protocol timepoints. Here is what those windows are, why they slip, and how clinic operations can close the gap.
Differentiated thyroid cancer follow-up depends on TSH suppression targets that should change as patient risk evolves. Most clinics lack the workflow infrastructure to track that change reliably.
When metastatic RCC patients transition from TKI therapy to immunotherapy, imaging intervals and response-assessment anchors frequently fall out of alignment. This piece walks clinic operators through why the gap opens and how structured software workflows can close it.
FLT3-ITD monitoring during AML consolidation therapy frequently slips due to scheduling gaps, assay limitations, and fragmented result routing. Here is what causes the gaps and what integrated workflows can do to close them.
Cytogenetic and mutation data in MDS crosses multiple provider boundaries in every care episode. Here is what HIPAA compliance requires at each handoff, and what gaps most multi-provider hematology workflows still carry.
About one in four endometrial cancer cases are MSI-H, a finding that reshapes the entire care pathway. Here is how structured software turns fragmented molecular testing data into actionable clinic records.
The evidence on MRD testing intervals in multiple myeloma is more specific than many clinic operations teams realise. This article covers what IMWG guidance and published trial data say about timing across transplant, maintenance, and CAR-T pathways.
Interim PET timing for lymphoma is narrower than most clinic workflows can reliably hit. This piece examines why mid-treatment re-staging intervals drift and what a protocol-aware scheduling layer does differently.
Post-surgery surveillance for colorectal cancer requires CEA tests, CT scans, and colonoscopy tracked across five years and multiple departments. Most clinics are not keeping up.
HER2-positive advanced gastric cancer affects 15 to 20 percent of patients, but local lab discordance rates of 12 percent or more mean results do not always drive treatment decisions in time. This is what the coordination gap looks like and how oncology clinics can close it.
Hereditary ovarian cancer programs generate some of the most sensitive data in clinical oncology. This article breaks down the security gaps, cascade testing workflows, and platform requirements that matter most for BRCA-positive patient records.
Active surveillance for low-risk prostate cancer depends on consistent PSA monitoring. This article explains how PSA velocity fits into a multi-signal protocol and how clinic software keeps that protocol from eroding through scheduling gaps and unstructured lab data.
EGFR, ALK, and PD-L1 results determine the first-line treatment path for NSCLC. Here is what clinic teams need to understand about each test and where workflow delays cost the most time.
Pancreatic cancer surveillance intervals lack a strong evidence base, and clinic workflows compound that uncertainty into real follow-up gaps. This article examines where post-resection monitoring breaks down and what operational fixes reduce recurrence detection delays.
Melanoma surveillance requires multi-year, stage-specific follow-up cadences that most generic scheduling tools are not built to track. Here is how clinic operators can prevent the gaps that form between protocol and calendar.
When a breast cancer patient sees both a conventional oncologist and an integrative provider, coordination failures are common and carry real clinical risk. This piece examines where the workflow breaks and what structured software coordination looks like in practice.
Product changes, clinical case studies, and short essays — straight from the people building Rucja.